Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.

@article{Stahel1994RandomizedSO,
  title={Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.},
  author={Rolf Arno Stahel and Lorenz M Jost and Thomas Cerny and Gabriella Pichert and Hanspeter Honegger and Andreas R Tobler and Emanuel Jacky and Martin Fey and Erich Platzer},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1994},
  volume={12 9},
  pages={1931-8}
}
PURPOSE The aim of this prospective randomized trial was to examine the efficacy and safety of filgrastim after high-dose chemotherapy and autologous bone marrow transplantation (ABMT). PATIENTS AND METHODS Patients with poor-risk non-Hodgkin's lymphoma or relapsed Hodgkin's disease were treated in a randomized, open-label trial to study the use of filgrastim as an adjunct to high-dose chemotherapy and ABMT. Of 43 assessable patients, 19 were randomized to receive filgrastim by continuous… CONTINUE READING